Amplia Therapeutics with CEO Chris Burns

00:00 – Intro & welcome to Chris Burns, CEO of Amplia 02:00 – Why pancreatic cancer is so deadly & hard to diagnose 06:30 – Current treatment options: Gem/Abraxane vs FOLFIRINOX 11:20 – Side effects & challenges with chemotherapy 15:00 – Why pancreatic cancer is difficult to treat (fibrosis & mutations) 19:00 – Amplia’s approach: FAK inhibitors and how they work 23:00 – History of FAK inhibitors & Amplia’s drug development story 27:00 – ACCENT trial design and early results (response rate, PFS) 32:00 – Complete responses & long-term responders (12–18+ months) 36:00 – Next steps: Simplicity trial with FOLFIRINOX 38:30 – Path to registrational trial & FDA fast track 41:00 – Combination opportunities: KRAS inhibitors & ADCs 43:00 – Commercial strategy, pricing, partnerships 44:30 – Wrap-up & final thoughts

You can listen to Amplia Therapeutics with CEO Chris Burns online on Radio and Podcast. Open the player on this page to stream the available audio.

Amplia Therapeutics with CEO Chris Burns is an episode from Double or Nothing! With Michael Frazis and Misha Saul by Michael Frazis.

This episode is 00:45:06 long.

This episode was published on Sep 19, 2025.

Yes. Use the heart button on the episode page to add it to your favorite episodes list.

Yes. This page shows related episodes from Double or Nothing! With Michael Frazis and Misha Saul when more episodes are available from the podcast feed.